Abstract 1134P
Background
The CPI combination of standard dose (SD) Ipi (3mg/kg) and nivolumab 1mg/kg (N) has dramatically improved outcomes in pts with MBM but is associated with frequent grade (gr) 3/4 adverse events (AEs). In pts without MBM, LD Ipi (at 1mg/kg) + anti-PD1 with N or Pem has demonstrated promising efficacy with reduced toxicity. We hypothesized this approach would have activity in pts with MBM.
Methods
We conducted a phase II, single arm and site trial (NCT03873818) evaluating LD Ipi + Pem in pts with MBM. Pts received up to 4 cycles of LD Ipi + Pem, followed by Pem only. At least 1 MBM >/= 5mm was required. CPI naïve (Cohort A) and prior PD-1 (Cohort B) were allowed. Primary objective included intracranial (IC) benefit rate (CBR) – complete response (CR) + partial response (PR) + stable disease (SD) ≥ 6 months (mos) by mRECIST 1.1. Secondary objectives were overall (OS) and progression free (PFS) survival. Study was terminated early due to accrual challenges. Here we report the efficacy results of cohort A.
Results
A total 19 of a planned 25 (76%) pts were treated in Cohort A. 58% (11) were male, median age was 63 years (23-88), 7 had BRAF V600 mutation. Median number of MBM was 3 (1-20), median diameter of largest MBM 8 mm (5-28). Pts received a median 4 cycles (1-4) of the combination, median total cycles received was 6 (1-35). IC CBR was 58% (32% CR, 11% PR, 16% SD). At a median follow-up of 14.5 mos (0.5-43), median IC PFS was 8.0 mos (95% CI 1.4- not reached) and median OS has not been reached. 11 (58%) pts in cohort A are alive at time of data lock. 25% (4/16) of pts stopped tx due to progression. 7 pts (37%) stopped tx for AEs. 16 pts experienced AEs at least possibly related to tx, most commonly rash (53%), fatigue (42%), and elevated liver enzymes (32%). Gr 3/4 AEs were observed in 6 (32%) pts, including rash (16%), elevated liver enzymes (11%), nausea, pneumonitis, anorexia, and colitis (5% each).
Conclusions
LD Ipi/Pem was well tolerated in CPI naïve pts with MBM, with no new or unexpected AEs, and with promising efficacy. The results support a larger study to confirm benefit.
Clinical trial identification
NCT03873818.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Merck.
Disclosure
I.C. Glitza: Financial Interests, Institutional, Speaker, Consultant, Advisor: Bristol Meyers Squibb, Array, Novartis, Sintetica; Financial Interests, Institutional, Principal Investigator: Bristol Meyers Squibb, Merck, Pfizer. R. Amaria: Financial Interests, Institutional, Principal Investigator: Bristol Meyers Squibb, Iovance, Obsidian, Merck. S. Patel: Financial Interests, Institutional, Principal Investigator: Bristol Meyers Squibb, Foghorn Therapeutics, InxMed, Novartis, Provectus, Reata Pharmaceuticals, TriSalus Life Sciences; Financial Interests, Personal, Advisory Board: Cardinal Health, Castle Biosciences; Financial Interests, Institutional, Other, Data Safety Monitoring Board: Immunocore; Financial Interests, Personal, Speaker, Consultant, Advisor: Advance Knowledge in Healthcare. A. Diab: Financial Interests, Institutional, Principal Investigator: Bristol Meyers Squibb. M. Wong: Financial Interests, Institutional, Advisory Board: Merck, Pfizer, Bristol Myers Squibb, Regeneron, EMD-Serono, ExiCure, Castle Biosciences. J. Mcquade: Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck; Financial Interests, Personal, Other, Honorarium: Bristol Myer Squibb, Roche. C. Yee: Financial Interests, Institutional, Speaker, Consultant, Advisor: Grey Wolf Therapeutics, Immatics, RootPath, T-Cypher Bio, GenomeFrontier Therapeutics, Achelios Oncology. M. Davies: Financial Interests, Institutional, Speaker, Consultant, Advisor: Roche/Genentech, Array, Pfizer, Novartis, Bristol Meyers Squibb, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, ABM Therapeutics; Financial Interests, Institutional, Principal Investigator: Roche/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon. H.A. Tawbi: Financial Interests, Institutional, Speaker, Consultant, Advisor: Bristol Meyers Squibb, Genentech, Novartis, Merck, Boxer Capital, Karyopharm, Iovance, Eisai Jazz, Medicenna; Financial Interests, Institutional, Principal Investigator: Bristol Meyers Squibb, Novartis, Merck, Genentech, GSK, EMD Serono, Eisai, Dragonfly Therapeutics, RAPT Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1119P - Stage IIIA melanoma with isolated tumor cells in lymph nodes: Time for reviewing the AJCC v8 classification
Presenter: Teresa Amaral
Session: Poster session 13
1120P - Development and external validation of a clinical prediction model to predict recurrence-free survival and melanoma-specific survival in patients with melanoma after sentinel lymph node biopsy
Presenter: Robert Stassen
Session: Poster session 13
1121P - Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1122P - Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?
Presenter: Maria Menezes
Session: Poster session 13
1123P - Baseline tumor-infiltrating lymphocytes and response to immune checkpoint inhibition in advanced melanoma
Presenter: Mark Schuiveling
Session: Poster session 13
1124P - IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis
Presenter: Domenico Mallardo
Session: Poster session 13
1125P - Identification of a subset of metastatic melanoma patients demonstrating germline determined insensitivity to immunotherapy
Presenter: Benjamin Fairfax
Session: Poster session 13
1126P - REtrospective Study of definitive therapy for head and neck mUcosal MElanoma: The RESUME study
Presenter: Motoo Nomura
Session: Poster session 13
1127P - Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis
Presenter: James Pham
Session: Poster session 13
1128P - A phase I dose escalation and expansion study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, for the treatment of metastatic uveal melanoma
Presenter: Sapna Patel
Session: Poster session 13